Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ACHV vs LCTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACHV Captures Overall Composite Edge (56.6 HOLD vs 54.9 HOLD), While LCTX Leads 3–2 on Growth & Valuation Pillars

ACHV Overall Winner 6-Pillar Tally: ACHV 2 – 3 LCTX (1 Tie) Matrix Metrics: ACHV 6 – 4 LCTX

As of Nov 20, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (56.6/100 HOLD vs. 54.9/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. ACHV trades at $6.78 (35.3x Forward P/E, 0.0% operating margin) versus LCTX at $0.77 (30.7x Forward P/E, -280.3% operating margin).

  • Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. LCTX 54.9/100 HOLD) and 1.73β · 62% Vol risk profile, whereas LCTX leads top-line expansion (-61.0% YoY revenue growth, 10.64x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACHV vs LCTX
ACHV NASDAQ Head-to-Head Winner
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
TTM Revenue N/A
Forward P/E 35.3x
Beta / 30D Vol 1.73β · 62% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $6.72 · SMA50: $7.28
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.39β · 79% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $0.97 · SMA50: $0.97

6-Pillar Scorecard Institutional Category Breakdown (ACHV 2 – 3 LCTX)

Columns: Metric · ACHV · LCTX
1. Valuation Multiples LCTX
Forward P/E 35.3x 30.7x
Trailing P/E 35.3x 30.7x
PEG Ratio 17.68x 10.64x
EV / Revenue N/M 15.9x
2. Growth & Scale ACHV
Revenue Growth (YoY) +0.0% -61.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $11M
Market Cap $692.8M $207.4M
3. Profitability & Quality LCTX
Gross Margin N/A -95.0%
Operating Margin 0.0% -280.3%
Net Profit Margin 0.0% 16.2%
Return on Equity (ROE) -845.0% 4.3%
4. Balance Sheet & Cash Flow LCTX
Cash Generation (TTM) -$44M -$24M
Cash Flow Margin N/A N/A
Net Cash / Leverage $46M Net Cash $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACHV
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 88.3% (23rd %ile) 0.0% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACHV (6) vs LCTX (4)
Institutional Metric ACHV LCTX Criterion Row Edge
Market Capitalization
Scale
$692.8M $207.4M Larger Scale ACHV
Trailing P/E Ratio
Valuation
35.3x 30.7x Lower Multiple LCTX
Forward P/E Ratio
Valuation
35.3x 30.7x Lower Multiple LCTX
Revenue Growth (YoY)
Growth
+0.0% -61.0% Higher Growth ACHV
Operating Margin (TTM)
Profitability
0.0% -280.3% Higher Margin ACHV
Net Profit Margin
Profitability
0.0% 16.2% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
-845.0% 4.3% Higher ROE LCTX
52-Week Range Position
Momentum
69% ($3–$9) 0% ($1–$2) Stronger Trend ACHV
Beta / 30D Volatility
Risk Regime
1.73β · 62% Vol 1.39β · 79% Vol Lower Realized Risk ACHV
Unified Institutional Score
Composite Signal
56.6 / 100 (HOLD) 54.9 / 100 (HOLD) Higher Composite ACHV
Trailing 12M Revenue (USD)
Operating Scale
N/A $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -95.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
17.68x PEG · N/M EV/Rev 10.64x PEG · 15.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$44M ($46M Net Cash) -$24M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LCTX +17.15 pp
ACHV: -8.5% · LCTX: +8.65%
3M Horizon ACHV +3.72 pp
ACHV: +0.15% · LCTX: -3.57%
6M Horizon ACHV +38.85 pp
ACHV: +21.29% · LCTX: -17.56%
1Y Horizon ACHV +93.78 pp
ACHV: +56.94% · LCTX: -36.84%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs LCTX. Trailing 12-month operating profitability (ACHV 0.0% vs LCTX -280.3%) and valuation multiples (ACHV 35.3x vs LCTX 30.7x Forward P/E) are benchmarked directly in Pillar 4 below.

ACHV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-845.0% · 35.3x
LCTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross Margin-95.0%
Op. Margin-280.3%
ROE / Fwd P/E4.3% · 30.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACHV BREAKOUT
125d in phase · OBV NEUTRAL
Current IV 88.3%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ACHV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
7d in phase · OBV DISTRIBUTION
Current IV 0.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACHV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $207.4M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACHV vs LCTX Key Questions & Quantitative Answers

As of Nov 20, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (56.6/100 HOLD vs. 54.9/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. ACHV trades at $6.78 (35.3x Forward P/E, 0.0% operating margin) versus LCTX at $0.77 (30.7x Forward P/E, -280.3% operating margin). Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. LCTX 54.9/100 HOLD) and 1.73β · 62% Vol risk profile, whereas LCTX leads top-line expansion (-61.0% YoY revenue growth, 10.64x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACHV leads the Growth & Scale pillar: ACHV posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LCTX at -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin). On trailing 12-month operating scale, ACHV generates N/A in USD-normalized revenue versus $11M for LCTX. In operating R&D and SG&A reinvestment, ACHV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCTX.

LCTX screens cheaper on headline valuation multiples. ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin), whereas LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 15.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACHV (-845.0% ROE) versus LCTX (4.3% ROE) capital efficiency.

In options market volatility and institutional positioning, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk). By comparison, LCTX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.